Adiponectin's Effect on Inflammation in Type 1 Diabetes
Author Information
Author(s): Abke Sabine, Neumeier Markus, Weigert Johanna, Wehrwein Gabriele, Eggenhofer Elke, Schäffler Andreas, Maier Kevin, Aslanidis Charalampos, Schölmerich Jürgen, Buechler Christa
Primary Institution: Department of Internal Medicine I, University of Regensburg
Hypothesis
How does adiponectin influence cytokine and chemokine release in monocytes from type 1 diabetes patients compared to controls?
Conclusion
Adiponectin-induced secretion of certain inflammatory markers is impaired in monocytes from type 1 diabetes patients.
Supporting Evidence
- Systemic adiponectin was found to be higher in type 1 diabetes patients compared to controls.
- IL-6 secretion was significantly lower in monocytes from type 1 diabetes patients when stimulated with adiponectin.
- CCL2 and CXCL8 were not induced in type 1 diabetes monocytes by adiponectin.
Takeaway
In people with type 1 diabetes, a substance called adiponectin doesn't help their immune cells release important signals as well as it does in healthy people.
Methodology
Monocytes were isolated from 10 type 1 diabetes patients and 10 controls, and their response to adiponectin was analyzed for cytokine release.
Potential Biases
Potential selection bias as only patients with intensive insulin treatment were included.
Limitations
The study only included female participants, which may limit the generalizability of the findings.
Participant Demographics
20 female participants, 10 with type 1 diabetes and 10 controls, median age of controls 24 years and patients 36.5 years.
Statistical Information
P-Value
0.04
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website